KRAS and pancreatic ductal adenocarcinoma: For instance, in a clinical study that evaluated the presence of mutant KRAS in plasma-derived EV DNA of early-stage pancreatic ductal adenocarcinoma (PDAC) patients, 66% of the patients (22/33 patients) were positive for mutant KRAS whereas only 7.4% of age-matched control samples were positive (152).